Alan Meds vs Navio MD
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Navio MD
Best for compounded tirzepatide with brand-name fallback across 48 statesStarting at $247/mo
Side-by-Side Comparison
| Feature | Alan Meds | Navio MD |
|---|---|---|
| Overall Score | ✓7.7/10 | 7.4/10 |
| Starting Price | ✓$99/mo | $247/mo |
| Editorial Rating | ✓3.9 ★ /5 | 3.7 ★ /5 |
| Features | 5 features | 5 features |
| States Available | 46 | ✓48 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Navio MD
Pros
- ✓LegitScript verified with board-certified providers and US-licensed pharmacies
- ✓Same price at every dose — no price escalation
- ✓Both compounded and brand-name options
- ✓48-state coverage
- ✓Hours 9am–10pm EST Mon–Sun
Cons
- ✗Not available in Alabama and Mississippi
- ✗Compounded option is tirzepatide only — no compounded semaglutide listed
- ✗Brand-name at near-retail pricing ($1,199–$1,249/mo)
- ✗Also offers women's HRT (broader platform)
Our Verdict
Alan Meds edges out Navio MD with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Navio MD remains a solid alternative, especially if you're looking for compounded tirzepatide with brand-name fallback across 48 states.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.